Biocon to speculate ₹2,200 crore in capex within the subsequent 2 years
Bengaluru-based biopharmaceutical firm Biocon Restricted lately launched their This autumn FY24 outcomes, indicating a 56.7 per cent decline in consolidated earnings to ₹135.5 crore in comparison with ₹313.2 crore in This autumn of the earlier 12 months. Siddharth Mittal, CEO & Managing Director, Biocon Restricted, spoke to businessline concerning the efficiency and outlook of the group’s … Read more